HepaTx Corp.
YC S18San Francisco, US · Founded 2015 · 4 employees · 2 known investors
HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.
Founders & leadership· Y Combinator alumni (S18)
Eric SchuurinChief Executive Officer, Co-Founder
Investors · 2
In the news
- Hepatx Corporation - BIO Investor Forum 2024bif.bio.org